Document is current
Any future updates will be listed below
-
Authors
Senapati, Jayastu https://orcid.org/0000-0002-6831-2567
Jabbour, Elias https://orcid.org/0000-0003-4465-6119
Short, Nicholas J. https://orcid.org/0000-0002-2983-2738
Jain, Nitin
Haddad, Fadi https://orcid.org/0000-0002-9702-8485
Bathala, Tharakeswara
Kovalenko, Iuliia https://orcid.org/0000-0003-4821-2195
Bidikian, Aram
Ravandi, Farhad https://orcid.org/0000-0002-7621-377X
Khouri, Issa
Kadia, Tapan M. https://orcid.org/0000-0002-9892-9832
Garris, Rebecca
Montalban Bravo, Guillermo
Chien, Kelly
Shpall, Elizabeth
Kebriaei, Partow
Kantarjian, Hagop M. https://orcid.org/0000-0002-1908-3307
- License Information
-
More Information
Article History
Received: 25 May 2024
Revised: 5 July 2024
Accepted: 10 July 2024
First Online: 7 August 2024
Competing interests
: EJ has received research grants and consultancy from Amgen, Adaptive Biotechnologies, Ascentage, Autolus, Bristol-Myers Squibb, Pfizer, Takeda, Novartis, Abbvie, Genentech, ASTX, TGRX, TERN, and Johnson and Johnson. NJS has been a consultant for Takeda Oncology, AstraZeneca, Amgen, Novartis, and Pfizer; received research funding from Takeda Oncology, Astellas, and Stemline Therapeutics; and received honoraria from Amgen. FR has received research funding from Amgen, Astex Pharmaceuticals/Taiho Oncology, Bristol Myers Squibb/Celgene, Syos, AbbVie, Prelude, Xencor, Astellas Pharma, and Biomea Fusion; honoraria from Amgen, Bristol Myers Squibb/Celgene, Syos, AbbVie, and Astellas Pharma; has been a board of directors or advisory committee member for Astex Pharmaceuticals/Taiho Oncology; and has been a consultant for Bristol Myers Squibb/Celgene, Syos, Novartis, AbbVie, AstraZeneca, and Astellas Pharma. TMK has been a consultant for AbbVie, Agios, Bristol Myers Squibb, Genentech, Jazz Pharmaceuticals, Novartis, Servier, and PinotBio; has received research funding from AbbVie, Bristol Myers Squibb, Genentech, Jazz Pharmaceuticals, Pfizer, Cellenkos, Ascentage Pharma, Galectin Therapeutics, Astellas Pharma, AstraZeneca, Amgen, Cyclacel Pharmaceuticals, Delta-Fly Pharma, Iterion Therapeutics, GlycoMimetics, and Regeneron Pharmaceuticals; and has received honoraria from Astex Pharmaceuticals. The remaining authors declare no competing financial interests. HMK has received research funding from AbbVie, Amgen, Ascentage Pharma, Bristol Myers Squibb, Daiichi Sankyo, ImmunoGen, Jazz Pharmaceuticals, and Novartis as well as honoraria from AbbVie, Amgen, Amphista Therapeutics, Ascentage Pharma, Astellas Pharma, Biologix, Curis, Ipsen, KAHR, Novartis, Pfizer, Precision BioSciences, Shenzhen TargetRx, and Takeda Oncology. All the other authors declare no relevant conflict of interest.
